

Limited distribution drug reimbursement change for facilities – new drug added

Effective for new prior authorizations obtained on or after May 1, 2018, we will no longer reimburse facilities that bill us for the cost of certain limited distribution drugs (LDDs) that are purchased directly from specialty pharmacies, manufacturers, or wholesalers.

The list has now been updated to include LUXTURNA™ (voretigene neparvovec-rzyl), effective May 1, 2018.

Network News now available

The April 2018 Network News is now available, and is attached.

CignaforHCP.com – new registration process pop-up screen and provider emails

As part of the new Cigna for Health Care Professionals (CignaforHCP.com) website registration process, beginning April 26, 2018, users who log in to the CignaforHCP.com website will see a pop-up screen asking them to complete a form that verifies their user contact information and identifies a website access manager for their group. Also on April 26, the first of three emails will be sent to registered users of the CignaforHCP.com website letting them know about the pop-up screen and requesting their response. The subsequent two emails will be sent on May 10 and May 24.

The new registration process will create a new way for all providers (medical, dental, and behavioral) and their staff to register for and obtain access to CignaforHCP.com. This should result in a faster, more seamless experience, as well as added security. These changes will enable future website enhancements. To accomplish this, we will be creating a new role – website access manager. This role will be assigned to one or more users at each practice. A fact sheet is available to share with providers, and is attached.

Drug formulary update for Copaxone injectable medication, effective July 1, 2018

Effective July 1, 2018, we will remove Copaxone® from our formulary and offer alternative clinically equivalent injectable and oral drugs. These drugs are commonly used to treat multiple sclerosis.

Cigna Specialty Pharmacy will fill current prescriptions for Copaxone with a preferred generic alternative at the customer's next time of refill, beginning July 1, 2018. A new prescription or prior authorization will not be required. The preferred alternative generic drugs being added to our formulary are Glatopa® and glatiramer acetate.

We will add several alternative preferred brand name drugs, both injectable and oral, to our formulary. Please note that these drugs will require prior authorization.

- Preferred brand name injectable drugs: Betaseron®, Extavia®, Plegridy®, Rebif®, and Avonex®
- Preferred brand name oral medications: Tecfidera®, Gilenya®, and Aubagio®

We will send letters to affected providers on April 25, 2018, and information about this update will appear in the April 2018 issue of Network News. We sent letters to affected customers on April 20, 2018.

#